XYone Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of XYA02(AT2021), a Novel Antibody Drug Conjugate targeting MUC1-C
Why now
Thesis: Private clinical milestone, limited read-through
Catalyst to watch: Interim Phase 1b/2 data
Main risk: Early-stage trial may fail
Why it matters
A private biotech's Phase 1b/2 dosing is early-stage and not tied to a listed ticker.
Details
CANTON, Mass., Sept. 29, 2026 /PRNewswire/ -- XYone Therapeutics, Inc. ("XYone"), a clinical-stage biotechnology company, announced that the first patient has been dosed in the first-in-human Phase 1b/2 clinical trial of XYA02(also known as AT2021), the Company's lead antibody-drug...
Sources
- prnewswire · 2026-09-29 14:03 UTC